Access cutting-edge multiple sclerosis treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access multiple sclerosis specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related multiple sclerosis treatment provided free
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. All participants will be followed for 72 months after randomization (Day 0, Visit 0).
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Check if you qualify for this multiple sclerosis clinical trial in Palo Alto, CA
If you're searching for multiple sclerosis treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple sclerosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.